Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

Vaduganathan Muthiah; Harrington Robert A.; Stone Gregg W.; Steg Ph. Gabriel; Gibson C. Michael; Hamm Christian W.; Price Matthew J.; Prats Jayne; Deliargyris Efthymios N.; Mahaffey Kenneth W.; White Harvey D.; Bhatt Deepak L.

首页> 外文期刊>Circulation. Cardiovascular interventions >Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

【24h】

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

机译：Cangrelor与标准疗法的美国和非美国亚组患者概况和结果的差异，以实现血小板抑制（CHAMPION）PHOENIX试验的最佳管理

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background-The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients undergoing percutaneous coronary intervention compared with clopidogrel.

机译：背景-Cangrelor与实现最佳血小板抑制管理的标准疗法（CHAMPION）的PHOENIX试验显示，与氯吡格雷相比，cangrelor在减少接受48小时经皮冠状动脉介入治疗的患者的缺血事件方面具有优势。

著录项

来源
《Circulation. Cardiovascular interventions 》 |2016年第6期| 共22页
作者
Vaduganathan Muthiah; Harrington Robert A.; Stone Gregg W.; Steg Ph. Gabriel; Gibson C. Michael; Hamm Christian W.; Price Matthew J.; Prats Jayne; Deliargyris Efthymios N.; Mahaffey Kenneth W.; White Harvey D.; Bhatt Deepak L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病 ;
关键词
antiplatelet therapy; clinical trial; international comparison; percutaneous coronary intervention; variation;

机译：抗血小板治疗;临床试验;国际比较;经皮冠状动脉介入治疗;变异;

相似文献

外文文献
中文文献

1. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial [J] . Vaduganathan Muthiah, Harrington Robert A., Stone Gregg W., Circulation. Cardiovascular interventions . 2016 ,第6期

机译：Cangrelor与标准疗法的美国和非美国亚组患者概况和结果的差异，以实现血小板抑制（CHAMPION）PHOENIX试验的最佳管理
2. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial [J] . ODonoghue Michelle L., Bhatt Deepak L., Stone Gregg W., Circulation: An Official Journal of the American Heart Association . 2016 ,第3期

机译：从经皮冠状动脉介入治疗与标准疗法的角度了解经皮冠状动脉介入治疗对女性和男性的作用和安全性，以实现血小板抑制的最佳管理（CHAMPION PHOENIX）
3. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) (vol 11, e005635, 2018) [J] . Groves E. M., Bhatt D. L., Steg P. G., Circulation. Cardiovascular interventions . 2018 ,第9期

机译：经皮冠状动脉干预后获得的血小板减少症的发病率，预测因子和结果：冠军试验的合并，患者水平分析（植物与标准治疗，实现血小板抑制的最佳管理）（第11卷，E005635,2018）
4. Hypotensive resuscitation versus standard fluid resuscitation for the management of trauma patients in hemorrhagic shock: The safety phase of a randomized controlled trial. [D] . Morrison, C. Anne. 2009

机译：低血压复苏与标准液体复苏在失血性休克中对创伤患者的处理：一项随机对照试验的安全性阶段。
5. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial [O] . Muthiah Vaduganathan, Robert A. Harrington, Gregg W. Stone, -1

机译：Cangrelor与标准疗法的美国和非美国亚组患者概况和结果的差异以实现血小板抑制（CHAMPION）PHOENIX试验的最佳管理
6. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial [O] . Vaduganathan M, Harrington RA, Stone GW, 2016

机译：美国和非美国Cangrelor亚组与标准治疗的患者概况和结果的变化，以实现血小板抑制的最佳管理（CHampION）pHOENIX试验

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

摘要

著录项

相似文献

相关主题

期刊订阅